Vave Pediatric Drops

Indications of Vave Drops

Gastroesophageal reflux and esophagitis are frequently related with delayed stomach emptying:

• Upper abdominal pain, feeling of abdominal distension, and epigastric fullness
• Eructation, flatulence, and early satiety are all symptoms of early satiety.
• Vomiting and nausea
• Regurgitation of stomach contents into the mouth, with or without heartburn
• Dyspepsia without ulcers
• Acute nausea and vomiting of functional, organic, infectious, or dietetic origin, as well as nausea and vomiting generated by radiotherapy or pharmacological therapy, and nausea and vomiting induced in migraine.
• Dopamine agonist-induced nausea and vomiting in Parkinson's disease.
• Increasing the speed of barium transit in follow-up radiological tests.

Pharmaceutical Name of Vave Drops

ACI Limited

Pharmacology

Domperidone may be a dopamine opponent that principally pieces the dopamine receptors found within the ChemoreceptorTrigger Zone (CTZ) and stomach. Its gastroprokinetic activity is based on its blocking impact of dopamine receptors that have an impact on the motility of the gastrointestinal tract. Due to its frail entrance over the blood-brain barrier, Domperidone has nearly no impact on the dopaminergic receptors within the brain, in this manner, barring psychotropic and neurologic side impacts. Domperidone reestablishes typical motility and tone of the upper gastrointestinal tract, encourages gastric purging, upgrades antral and duodenal peristalsis and directs withdrawal of the pylorus. Domperidone too increments esophageal peristalsis and lower esophageal sphincter weight, and hence anticipates spewing forth of gastric content.

Dosage & Administration

Domperidone should be taken 15-30 minutes before meals and, if necessary, before retiring.

The usual recommended oral dose of Domperidone is as follows:

• Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily. The maximum dose of Domperidone is 80 mg daily.
• Children: 2-4 ml suspension/10 kg body weight or 0.4-0.8 ml paediatric drops/10 kg body weight, every 6-8 hours daily.

In dyspeptic symptom:

• Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily.
• Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily.

In acute and sub-acute conditions (mainly in acute nausea and vomiting):

• Adults: 20 mg (2 tablets or 20 ml suspension), every 6-8 hours daily
• Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily. (In acute nausea and vomiting maximum period of treatment is 12 weeks).

By rectum in suppositories:

• Adults (including elderly): 30-60 mg every 4-8 hours.
• Children: The maximum daily dose rectally in children's is 30 mg for those weighting 10 to 25 kg. The dose may be divided throughout day if necessary.
• The maximum period of treatment is 12 weeks.

Interaction of Vave Drops

Domperidone may reduce the risk of hypoprolactemic effect of bromocriptine. The action of Domperidone on Gl function may be antagonized by antimuscarinics and opoid analgesics. Care should be exercised when domperidone is administered in combination with MAO (monoamine oxidase) inhibitors.

Contraindications

Domperidone may reduce the risk of hypoprolactemic effect of bromocriptine. The action of Domperidone on Gl function may be antagonized by antimuscarinics and opoid analgesics. Care should be exercised when domperidone is administered in combination with MAO (monoamine oxidase) inhibitors.

Side Effects of Vave Drops

Hyperprolactinemia is a side effect of domperidone (1.3 percent ). Galactorrhea, breast growth, discomfort, and a decrease in libido are all possible side effects. During domperidone treatment, dry mouth (1 percent), thirst, headache (1.2 percent), nervousness, drowsiness (0.4 percent), diarrhea (0.2 percent), skin rash, and itching (0.1 percent) are all possible side effects. Clinical investigations show that extrapyramidal responses occur in 0.05 percent of patients.

Pregnancy & Lactation

Because the safety of domperidone has not been established, it is not recommended for use during pregnancy. The teratogenic effect in the fetus has not been shown in animal research. Domperidone can help with galactorrhea and postpartum lactation. It's secreted in breast milk, but in such small amounts that it's not considered dangerous.

Precautions & Warnings

Domperidone should be used with extreme caution in children due to an elevated risk of extrapyramidal effects due to an incompletely established blood-brain barrier in young children. Domperidone should be taken with caution in patients with hepatic impairment since it is highly metabolized in the liver.

Therapeutic Class

Prokinetic medicines, Motility stimulants/Dopamine antagonists, Motility stimulants/Dopamine antagonists.

Storage Conditions

Store at or below 30°C, away from light and moisture. Keep out of reach of youngsters.